Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017, Article ID 1902708, 8 pages
Clinical Study

A Randomized Controlled Trial of Chinese Medicine on Nonmotor Symptoms in Parkinson’s Disease

1School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong
2Mr. & Mrs. Ko Chi Ming Centre for Parkinson’s Disease Research, Hong Kong Baptist University, Kowloon, Hong Kong
3Institutes of Integrative Medicine, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Sha Tin, Hong Kong
4State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau
5Department of Mathematics, Statistics Research & Consultancy Centre, Faculty of Science, Hong Kong Baptist University, Kowloon, Hong Kong

Correspondence should be addressed to Vincent Mok; kh.ude.khuc@komtcv and Min Li; kh.ude.ubkh@nimil

Received 23 January 2017; Accepted 28 February 2017; Published 23 May 2017

Academic Editor: Hélio Teive

Copyright © 2017 Ka-Kit Chua et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Nonmotor symptoms (NMS) of Parkinson’s disease (PD) have devastating impacts on both patients and their caregivers. Jiawei-Liujunzi Tang (JLT) has been used to treat some NMS of PD based on the Chinese medicine theory since Qing dynasty. Here we report a double-blind, randomized, placebo-controlled, add-on clinical trial aiming at evaluating the efficacy and safety of the JLT in treating NMS in PD patients. We randomly assigned 111 patients with idiopathic PD to receive either JLT or placebo for 32 weeks. Outcome measures were baseline to week 32 changes in Movement Disorder Society-Sponsored Revision of Unified PD Rating Scale (MDS-UPDRS) Parts I–IV and in NMS assessment scale for PD (NMSS). We observed improvements in the NMSS total score (), mood/cognition (), and reduction in hallucinations (). In addition, post hoc analysis showed a significant reduction in constipation (). However, there was no evidence of improvement in MDS-UPDRS Part I total score () at week 32. Adverse events (AEs) were mild and comparable between the two groups. In conclusion, long-term administration of JLT is well tolerated and shows significant benefits in improving NMS including mood, cognition, and constipation.